Lykos Moves Forward in Psychiatry After FDA MDMA Setback for PTSD Treatment
Strategic Reorganization to Enhance MDMA Therapy Development
Lykos Therapeutics is committed to advancing innovative treatments for post-traumatic stress disorder (PTSD) through a strategic reorganization. Following the FDA's recent rejection of its new drug application for MDMA capsules, the company is realigning its focus towards psychiatry and enhancing its clinical development efforts.
Workforce Adjustment and Continued Efforts
- Reducing workforce by approximately 75% to streamline operations.
- Focusing remaining team on clinical development, medical affairs, and FDA engagement.
Independent Advisory Board for Guidance
As part of its restructuring, Lykos has established an Independent Advisory Board. This board will guide the company in ensuring effective collaboration with behavioral health facilities and support organizations, particularly for veterans and survivors of sexual violence. Lykos's ongoing mission remains centered on addressing PTSD through innovative therapies.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.